Medicus Pharma (MDCX) Stock Price, News & Analysis

Company Overview

Medicus Pharma, Inc., traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies. Its research and development efforts are centered on expanding a pipeline that includes additional oncology supportive care candidates as well as treatments aimed at acute neurological and critical conditions. The company partners with established contract manufacturers and distributors to facilitate efficient production and market access.

Medicus Pharma primarily serves the U.S. market through a network of specialty pharmacies and hospital systems and is evaluating opportunities for international distribution. Led by a management team with experience in specialty pharmaceuticals, regulatory affairs and commercial operations, the company remains focused on advancing its pipeline and delivering targeted support therapies for patients undergoing cancer treatment and acute care interventions.

Key Stats

• Today's Range: $0.27 to $0.28
• 50-Day Range: $0.26 to $0.49
• 52-Week Range: $0.24 to $3.05
• Volume: 842,049 shs
• Average Volume: 2.02 million shs
• Market Capitalization: $17.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

Medicus Pharma Stock Analysis - MarketRank™

Medicus Pharma scored higher than 39% of companies evaluated by MarketBeat, and ranked 658th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Medicus Pharma has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Medicus Pharma has a consensus price target of $9.00, representing about 3,211.3% upside from its current price of $0.27.

Amount of Analyst Coverage

Medicus Pharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Medicus Pharma are expected to grow in the coming year, from ($0.73) to ($0.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Medicus Pharma is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Medicus Pharma is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.78% of the float of Medicus Pharma has been sold short.

Short Interest Ratio / Days to Cover

Medicus Pharma has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Medicus Pharma has recently increased by 5.94%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Medicus Pharma does not currently pay a dividend.

Dividend Growth

Medicus Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: -0.78

News Sentiment

Medicus Pharma has a news sentiment score of -0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Medicus Pharma this week, compared to 5 articles on an average week.

Search Interest

Only 7 people have searched for MDCX on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.

MarketBeat Follows

17 people have added Medicus Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 325% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Medicus Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.10% of the stock of Medicus Pharma is held by insiders.

Percentage Held by Institutions

Medicus Pharma has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 8/22/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:MDCX
• Previous Symbol: NASDAQ:MDCX
• CIK: 1997296
• Web: www.medicuspharma.com
• Phone: 732-300-3046
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Medicus Pharma: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +3,211.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.46 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -3,137.84%
• Return on Assets: -263.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.57
• Quick Ratio: 1.57

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.03) per share
• Price / Book: -9.06

Miscellaneous

• Outstanding Shares: 63,180,000
• Free Float: 58,063,000
• Market Cap: $17.17 million
• Optionable: N/A
• Beta: 0.11